STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZNTL
  4. [8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event

Zentalis names new Chief Legal Officer after resignation

Zentalis Pharmaceuticals, Inc. reported a leadership transition in its legal function.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Zentalis Pharmaceuticals, Inc. reported a leadership transition in its legal function. On August 26, 2025, Andrea Paul notified the Board of her intent to resign as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, to join the partnership of a large international law firm. She will remain a non-executive employee through October 1, 2025.

The company and Ms. Paul expect to enter into a release agreement that will provide payment of her 2025 target annual bonus and continued vesting of her equity awards during a transitional services period, after which certain awards will vest in full. In connection with her resignation, Zentalis appointed James B. Bucher as its new Chief Legal Officer and Corporate Secretary, effective September 18, 2025. The company describes Mr. Bucher as a seasoned life sciences legal executive with extensive public company and strategic transaction experience.

Positive

  • None.

Negative

  • None.

Insights

Orderly legal leadership handoff with successor named and transition support.

Zentalis Pharmaceuticals is managing a planned change in its top legal role. The Chief Legal Officer and Corporate Secretary, Andrea Paul, plans to resign effective September 18, 2025 to join a large international law firm, and will remain a non-executive employee through October 1, 2025. This staged departure and continued service suggests an organized transition rather than an abrupt exit.

The expected release agreement provides Ms. Paul with her 2025 target annual bonus and continued vesting of equity awards during a transitional services period, with some awards vesting in full afterward. These terms indicate the company is compensating her for supporting the handover and preserving continuity in legal and governance matters.

Concurrently, the Board appointed James B. Bucher as the new Chief Legal Officer and Corporate Secretary, effective September 18, 2025. The description of Mr. Bucher as a seasoned life sciences legal executive with extensive public company and strategic and financial transaction experience points to an effort to maintain experienced legal leadership as the company continues its operations and potential future transactions.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Zentalis Pharmaceuticals (ZNTL) disclose in this 8-K?
Zentalis Pharmaceuticals disclosed that its Chief Legal Officer and Corporate Secretary, Andrea Paul, informed the Board on August 26, 2025 of her intent to resign from that role, effective September 18, 2025.

How long will Andrea Paul remain with Zentalis Pharmaceuticals (ZNTL) after resigning her officer role?
After resigning as Chief Legal Officer and Corporate Secretary effective September 18, 2025, Andrea Paul will remain a non-executive employee through October 1, 2025.

What compensation and equity treatment will Andrea Paul receive in connection with her transition at Zentalis?
Zentalis and Andrea Paul expect to enter a release agreement under which she will receive payment of her 2025 target annual bonus and continued vesting of her equity awards during a transitional services period, after which certain awards will vest in full.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001725160FALSE00017251602025-08-262025-08-26


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
——————————————

FORM 8-K
——————————————

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 26, 2025

——————————————  
ZENTALIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)   
——————————————
Delaware 001-39263 82-3607803
(State or other jurisdiction
of incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
10275 Science Center Drive, Suite 200
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 263-4333
(Registrant’s telephone number, include area code)
N/A
(Former name or former address, if changed since last report)  
——————————————
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 



Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareZNTLThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 26, 2025, Andrea Paul informed the Board of Directors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) of her intent to resign as Chief Legal Officer and Corporate Secretary of the Company, effective as of September 18, 2025, in order to join the partnership of a large, international law firm. Following her resignation from this role, Ms. Paul will remain a non-executive employee of the Company through October 1, 2025. The Company and Ms. Paul expect to enter into a release agreement, pursuant to which Ms. Paul will be entitled to payment of her 2025 target annual bonus and continued vesting of her equity awards during a transitional services period, after which certain awards will vest in full. In connection with Ms. Paul’s resignation, the Company appointed James B. Bucher as the Company’s new Chief Legal Officer and Corporate Secretary, effective as of September 18, 2025. Mr. Bucher is a seasoned life sciences legal executive who has extensive public company experience, including broad strategic and financial transaction expertise.

Item 7.01 Regulation FD Disclosure.
On August 26, 2025, the Company issued a press release related to the above-referenced transition, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and incorporated herein by reference.

The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit shall be deemed to be furnished, and not filed:
Exhibit No.
 Description
99.1
 
Press Release issued on August 26, 2025
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 ZENTALIS PHARMACEUTICALS, INC.
Date: August 26, 2025 By: /s/ Julie Eastland
  Julie Eastland
  President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Keep reading

More on ZNTL

Trending in the feed

Open the live feed